First Patient Receives Antibody-based Prostate Cancer Treatment TLX591
The first patient has received TLX591, an antibody-based treatment for PSMA-positive metastatic castrate-resistant prostate cancer.
Source: curetoday.com
Genesiscare Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Genesiscare Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Genesiscare Group Today - Breaking & Trending Today
First Patient Enrolled in ProstACT TARGET Study
MELBOURNE, Australia, Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix's prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a first recurrence of...
Source: asiaone.com
Telix Pharmaceuticals Limited: First Patient Enrolled in ProstACT TARGET Study
MELBOURNE, Australia, Sept. 26, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care in Australia
Source: finanznachrichten.de
First Patient Enrolled in ProstACT TARGET Study
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care in Australia,...
Source: prnewswire.com
First Patient Enrolled in ProstACT TARGET Study
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care in Australia,...
Source: prnewswire.com